Pancreatic cancer: Tackling the tumour by targeting its surroundings

June 28, 2013
Pancreatic cancer: Tackling the tumour by targeting its surroundings
Credit: Shutterstock

With fewer than 5 percent of sufferers surviving beyond five years of diagnosis, pancreatic cancer is one of the most lethal of all cancers. Late diagnosis is one reason for these statistics, but so is the aggressive nature of the tumour and its resistance to the drugs used during chemotherapy.

An array of and molecular targeted therapies have succeeded in slowing or stopping tumour growth in cell culture and mouse experiments, but they have failed to have any impact in patients with pancreatic cancer taking part in clinical trials.

The EPC-TM-NET ('Targeting the tumour microenvironment to improve pancreatic cancer prognosis') project is tackling the disease from a different angle. Instead of focusing on the tumour itself, the team is using its EUR 3 million grant from the EU's Seventh Framework Programme (FP7) to study the microenvironment surrounding the tumour. Recent research has shown that a tumour's microenvironment, including blood vessels, and a variety of other cells, play a major role keeping under control.

Solid cancerous tumours found in the pancreas tend to be surrounded by very high levels of desmoplasia - fibrous or connective tissues. This, in addition to evidence that having chronic inflammatory increases the risk of developing pancreatic cancer, indicates to scientists that the tumour microenvironment is of particular importance for the spread of cancer in the pancreas.

The hope is that by understanding how the tumour's microenvironment is causing the failure of oncological treatments, the EPC-TM-NET team will be able to increase the survival rate of pancreatic cancer patients.

The team is using innovative in-vitro and mouse models that closely mimic the human disease to see exactly what happens when treatment fails. They will get a much clearer picture of the mechanics involved in the between the microenvironment's components and , their resistance to chemotherapy, and how the cancer spreads. There has also been a study on the effect of smoking (smoke exposure) and chronic pancreas inflammation on the tumour progression using mouse models.

Once the team has identified the stromal cells (connective tissue) that mediate the spread of cancer and chemoresistance, they will be able to pinpoint novel drug targets.

The EPC-TM-NET team brings together researchers from Germany (Philipps Universität Marburg, coordinating), Italy, Spain, Sweden and the UK. The clinical groups involved have expertise in pathology, gastrointestinal oncology and surgical oncology, while the pharmaceutical companies are specialised in drug development.

Explore further: Nanotechnology helps track and improve drug action in pancreatic cancer

More information:

Related Stories

Nanotechnology helps track and improve drug action in pancreatic cancer

June 12, 2013
(Medical Xpress)—UK and Australian scientists have been able to show ways in which we can markedly improve drug targeting of solid tumours, using tiny 'biosensors' along with new advanced imaging techniques.

Pancreatic cancer diagnosis under review

April 23, 2013
A team of researchers of the UPV/EHU together with researchers from the Hospital Clínico of Barcelona have produced a bibliographical review that summarises the data currently existing on the markers for pancreatic cancer, ...

Team creates realistic 3-D tumour through tissue engineering using silk scaffolds

June 20, 2013
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track ...

Scientists find gene that inhibits pancreas cancer spread

April 29, 2012
Scientists have identified a gene that slows the spread of pancreatic cancer tumours, paving the way for targeted treatment of one of the deadliest forms of the disease, said a paper published Sunday.

Scientists develop simple blood test to track tumour evolution in cancer patients

May 3, 2013
By tracking changes in patients' blood, Cambridge scientists have created a new way of looking at how tumours evolve in real-time and develop drug resistance. The research was published in the print edition of Nature today.

Diagnosis and management of pancreatic cancer: A review for physicians

April 22, 2013
Pancreatic cancer is the fourth leading cause of death from cancer, and while family physicians in Canada only see 1 cases a year, the number of cases is expected to increase as the population ages. A review in CMAJ (Canadian ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.